Mereo BioPharma Group plc filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 9, 2026, reporting a net cash position of $26.1 million and a widening accumulated deficit.
Key Highlights
- Cash position: Cash and cash equivalents stood at $26,097 thousand as of September 30, 2026, down from $40,992 thousand at December 31, 2025, according to the filing.
- Accumulated deficit: The company reported an accumulated deficit of $520,406 thousand at September 30, 2026, compared with $501,018 thousand at December 31, 2025.
- Nine-month operating loss: Loss from operations for the nine months ended September 30, 2026 was $22,014 thousand, versus $31,717 thousand for the same period in 2025.
- Quarterly revenue: Revenue for the three months ended September 30, 2026 was $800 thousand; total nine-month revenue was also $800 thousand, compared with $500 thousand for the nine months ended September 30, 2025.
- Research and development expenses: R&D expenses for the nine months ended September 30, 2026 were $8,645 thousand, down from $13,573 thousand in the comparable prior-year period.
- Shares outstanding: As of November 6, 2026, the company reported 798,503,184 ordinary shares outstanding, par value £0.003 per share.
- Total assets: Total assets were $29,583 thousand at September 30, 2026, compared with $45,917 thousand at December 31, 2025.
Mereo BioPharma's Financial Position for the Quarter Ended September 30, 2026
Mereo BioPharma Group plc (NASDAQ:MREO), incorporated in England and Wales, disclosed its condensed consolidated financial results for the three and nine months ended September 30, 2026. According to the filing, cash and cash equivalents declined to $26,097 thousand from $40,992 thousand at year-end 2025, while total assets fell to $29,583 thousand from $45,917 thousand over the same period. Total shareholders' equity was reported at $23,711 thousand, down from $40,916 thousand at December 31, 2025.
The filing shows that general and administrative expenses for the nine months ended September 30, 2026 were $14,169 thousand, compared with $18,811 thousand for the nine months ended September 30, 2025. Research and development expenses also declined, to $8,645 thousand from $13,573 thousand in the prior-year period. The company reported interest income of $846 thousand for the nine-month period ended September 30, 2026, versus $1,752 thousand in the comparable 2025 period. Changes in the fair value of warrants contributed a gain of $21 thousand for the nine months ended September 30, 2026, against a gain of $511 thousand in the same prior-year period.
On the balance sheet, accounts payable were $1,004 thousand and accrued expenses were $3,017 thousand as of September 30, 2026. Warrant liabilities totaled $16 thousand in aggregate (current and non-current combined). The company noted in its forward-looking statements section that risks include "the sufficiency of existing cash to fund operations and/or the inability to raise additional funding on favorable terms or at all" and "the Company's ability to maintain compliance with Nasdaq continued listing requirements," among other factors listed in the filing.
What Was Disclosed
Mereo BioPharma filed a quarterly report covering the period ended September 30, 2026, disclosing a cash balance of $26,097 thousand, a nine-month operating loss of $22,014 thousand, reduced R&D and G&A expenses versus the prior year, and an accumulated deficit of $520,406 thousand.




Please wait processing your request...